HC Wainwright Forecasts Higher Earnings for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities researchers at HC Wainwright lifted their FY2025 EPS estimates for Kodiak Sciences in a research note issued to investors on Thursday, January 22nd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($4.29) for the year, up from their previous estimate of ($4.35). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($3.13) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($2.33) EPS and FY2029 earnings at ($0.57) EPS.

Several other equities research analysts also recently commented on KOD. Lifesci Capital initiated coverage on shares of Kodiak Sciences in a research report on Thursday, October 23rd. They set an “outperform” rating and a $40.00 target price for the company. JPMorgan Chase & Co. raised shares of Kodiak Sciences from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $15.00 to $24.00 in a report on Friday, October 24th. Chardan Capital reaffirmed a “neutral” rating and set a $14.00 price objective on shares of Kodiak Sciences in a report on Monday, November 17th. Wall Street Zen lowered Kodiak Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kodiak Sciences has a consensus rating of “Moderate Buy” and an average target price of $28.29.

Kodiak Sciences Trading Down 4.4%

NASDAQ KOD opened at $24.53 on Monday. The firm has a market capitalization of $1.30 billion, a PE ratio of -5.95 and a beta of 2.67. The business’s 50-day moving average price is $25.63 and its two-hundred day moving average price is $16.91. Kodiak Sciences has a 12 month low of $1.92 and a 12 month high of $31.18.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.09).

Insider Activity at Kodiak Sciences

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker bought 2,608,696 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was bought at an average cost of $23.00 per share, for a total transaction of $60,000,008.00. Following the completion of the transaction, the director owned 18,358,772 shares of the company’s stock, valued at $422,251,756. This represents a 16.56% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 45.90% of the stock is owned by corporate insiders.

Institutional Trading of Kodiak Sciences

Large investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its position in Kodiak Sciences by 55.1% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company’s stock worth $7,668,000 after buying an additional 730,000 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Kodiak Sciences by 1.2% during the 2nd quarter. Acadian Asset Management LLC now owns 1,969,876 shares of the company’s stock worth $7,343,000 after acquiring an additional 23,742 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Kodiak Sciences by 7.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,950,292 shares of the company’s stock valued at $31,926,000 after purchasing an additional 127,991 shares in the last quarter. Boone Capital Management LLC acquired a new stake in Kodiak Sciences in the third quarter valued at about $11,719,000. Finally, Nantahala Capital Management LLC lifted its holdings in shares of Kodiak Sciences by 11.3% in the second quarter. Nantahala Capital Management LLC now owns 590,884 shares of the company’s stock worth $2,204,000 after acquiring an additional 60,171 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.